CN110114066B - 含沙丁胺醇的眼科药物 - Google Patents

含沙丁胺醇的眼科药物 Download PDF

Info

Publication number
CN110114066B
CN110114066B CN201780052188.6A CN201780052188A CN110114066B CN 110114066 B CN110114066 B CN 110114066B CN 201780052188 A CN201780052188 A CN 201780052188A CN 110114066 B CN110114066 B CN 110114066B
Authority
CN
China
Prior art keywords
composition
administered
eye
concentration
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780052188.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110114066A (zh
Inventor
拉乌夫·雷基克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN110114066A publication Critical patent/CN110114066A/zh
Application granted granted Critical
Publication of CN110114066B publication Critical patent/CN110114066B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780052188.6A 2016-06-27 2017-06-27 含沙丁胺醇的眼科药物 Active CN110114066B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TNTN2016/0259 2016-06-27
TN2016000259A TN2016000259A1 (en) 2016-06-27 2016-06-27 Salbutamol (albuterol) eye protective medicament.
PCT/IB2017/000779 WO2018007864A1 (en) 2016-06-27 2017-06-27 Salbutamol-containing ophthalmic medicament

Publications (2)

Publication Number Publication Date
CN110114066A CN110114066A (zh) 2019-08-09
CN110114066B true CN110114066B (zh) 2023-06-27

Family

ID=59416735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780052188.6A Active CN110114066B (zh) 2016-06-27 2017-06-27 含沙丁胺醇的眼科药物

Country Status (8)

Country Link
US (1) US11484513B2 (enExample)
EP (1) EP3474836B1 (enExample)
JP (1) JP7176960B2 (enExample)
CN (1) CN110114066B (enExample)
CA (1) CA3028924A1 (enExample)
MA (1) MA45457A (enExample)
TN (1) TN2016000259A1 (enExample)
WO (1) WO2018007864A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL321899A (en) * 2019-03-02 2025-09-01 Intrabio Ltd Leucine, acetyl leucine and related analogs for the treatment of disease
MX2021014357A (es) * 2019-06-10 2022-02-22 Jenivision Inc Metodos y formulaciones para tratar trastornos de la vision.
JP7066293B2 (ja) * 2019-11-12 2022-05-13 株式会社ファンケル サーチュイン１（ｓｉｒｔ１）発現増強用組成物
CN120916785A (zh) * 2023-04-08 2025-11-07 林颂然 治疗角膜损伤的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985897A (en) * 1973-12-21 1976-10-12 Mead Johnson & Company Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines
SE8701258D0 (sv) * 1987-03-26 1987-03-26 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
WO2001041806A1 (en) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
KR20040080439A (ko) 2001-12-12 2004-09-18 파마시아 코포레이션 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법
EP2311793A1 (en) 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
CA2780453A1 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
EP2808010A1 (en) * 2013-05-28 2014-12-03 Sanovel Ilac Sanayi ve Ticaret A.S. Syrup Formulation of Salbutamol

Also Published As

Publication number Publication date
US11484513B2 (en) 2022-11-01
JP2019524679A (ja) 2019-09-05
RU2018146575A (ru) 2020-07-28
US20190160027A1 (en) 2019-05-30
EP3474836B1 (en) 2024-01-17
CN110114066A (zh) 2019-08-09
EP3474836A1 (en) 2019-05-01
CA3028924A1 (en) 2018-01-11
WO2018007864A1 (en) 2018-01-11
EP3474836C0 (en) 2024-01-17
RU2018146575A3 (enExample) 2020-09-24
MA45457A (fr) 2019-05-01
TN2016000259A1 (en) 2017-10-06
JP7176960B2 (ja) 2022-11-22

Similar Documents

Publication Publication Date Title
Lee et al. Glaucoma and its treatment: a review
CA2718161C (en) Drug delivery to the anterior and posterior segments of the eye using eye drops
JP2025168426A (ja) 眼科用医薬組成物及びそれに関する使用
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
CN110114066B (zh) 含沙丁胺醇的眼科药物
JP2013544275A (ja) 葉酸−ラミプリルの組合せ：細胞保護性、神経保護性、および網膜保護性の眼科用組成物
JP2005501100A (ja) 視力を改善する生理学的方法
Gonzalez-Salinas et al. Patient considerations in cataract surgery–the role of combined therapy using phenylephrine and ketorolac
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
Wood et al. Rare corneal complication following selective laser trabeculoplasty
Tsujinaka et al. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution.
Galloway et al. The Ageing Eye
RU2774971C2 (ru) Офтальмологическое лекарственное средство, содержащее сальбутамол
Grzybowski et al. Post-cataract cystoid macular oedema prevention–update 2019
Wasik et al. Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma
Stradiotto et al. Glaucoma pharmacology
Kartasasmita et al. The effectiveness of continuous intravitreal adrenaline as mydriatic adjuvant on pars plana vitrectomy in diabetic patient, a randomized clinical trial
Mentes et al. Do mydriatics effect serous pigment epithelial detachment elevation? A case report on central serous chorioretinopathy
Berco et al. Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes
Barton et al. Sharing best practice and landmark evidence in glaucoma care
Dada et al. Medical Management of glaucoma
Song et al. Success in The Duke Elder Examination: 180 MCQs
Ramlal Interventional Follow Up Study of Resolution of Macular Edema After Intravitreal Triamcinolone Injection in Pseudophakic Patients with Macular Edema More than 350 Micron
Besada et al. Recurrent serous macular detachment after topical ocular hypotensive medication
Schellack et al. Glaucoma: a brief update for 2017

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant